Out of all the medical artificial intelligence promises made over time, a single instance has crossed the entire finish line: a randomized trial, a prespecified primary endpoint, and a published outcome. Focus on breast cancer screening, specifically through the MASAI trial. Spanning 105,934 women randomly assigned across the national screening initiative in Sweden, artificial intelligence-assisted analysis uncovered 29% more malignancies compared to traditional double interpretation—all while keeping false positives steady and slashing reading burdens by 44%. Furthermore, 2026 brought forward the previously missing metric: interval cancers, which serves as the definitive benchmark for evaluating whether a screening protocol remains safe. This piece breaks down the significance of this milestone and highlights what makes it truly unique.
The 30-second summary: the seven figures that matter
Each row lists the study alongside its publication year. Be aware that the initial three entries represent consecutive papers stemming from the exact same trial.
| Finding | Result | Study and year |
|---|---|---|
| Cancers detected per 1,000 women screened | 6.4 against 5.0; ratio of 1.29 (95% CI: 1.09-1.51; p = 0.0021) | Hernström et al., Lancet Digital Health (2025) |
| False positives | No increase: ratio of 1.01 (95% CI: 0.91-1.11; p = 0.92) | Hernström et al., Lancet Digital Health (2025) |
| Radiologist reading workload | 44.2% fewer reads | Hernström et al., Lancet Digital Health (2025) |
| Interval cancers, the primary endpoint | 1.55 against 1.76 per 1,000; ratio of 0.88, non-inferior | Gommers et al., The Lancet (2026) |
| Screening sensitivity | 80.5% against 73.8% (p = 0.031), at the same specificity | Gommers et al., The Lancet (2026) |
| Real-world rollout in Germany, 463,094 women | 6.7 against 5.7 per 1,000: 17.6% more detection | Eisemann et al., Nature Medicine (2025) |
| Reading reduction across 31 reviewed studies | Between 40% and 90% with triage strategies | Jassim et al., BMJ Open (2025) |
What you will find here
- How MASAI is designed and why its design differs from the rest.
• What an interval cancer is and why it was the missing figure.
- What transpired when it was administered to 463,094 women beyond the scope of a clinical trial.
- What the systematic review says is still unresolved.
1. The trial: how it was done
MASAI was conducted as part of the national screening initiative in Sweden, taking place across four distinct facilities situated in the country’s south-western region. During the timeframe spanning from April 2021 through December 2022, 105,934 female participants were allocated at random in a 1:1 ratio to undergo either artificial intelligence-assisted evaluation or conventional double reading devoid of AI. The median participant age stood at 53.7 years. Assignment was carried out automatically via the image archiving platform immediately following acquisition, ensuring that the interpreting radiologists remained blinded to the group assignment of each individual case.
The utility operates under a dual approach, and drawing a distinction matters since the final outcome hinges on it. The software rates every assessment on a ten-tier scale to determine if the screening requires single or double evaluation, while simultaneously highlighting suspicious areas for the attending radiologist. It never supplants human judgment; rather, it reorganizes workflow and directs attention.
The detection results, published in Lancet Digital Health in 2025: 6.4 cancers per 1,000 women screened in the AI group against 5.0 in the control group, a ratio of 1.29 (95% CI: 1.09-1.51; p = 0.0021).
What other types of cancer were identified
This question is what separates a useful screening programme from one that merely generates diagnoses. The additional detection was mostly of small invasive cancers without nodal involvement: 58 more T1 tumours, 46 more lymph-node negative, and 21 more of subtypes other than luminal A. In situ carcinomas also increased, and about half of that increase was high grade.
And what did not happen: neither the recall rate nor the false-positive rate rose significantly, while the positive predictive value of recall improved with a ratio of 1.19 (95% CI: 1.04-1.37; p = 0.012). Reading workload fell from 109,692 to 61,248 reads: 44.2% fewer.
| Study | What it contributed | Result | What it cannot support |
|---|---|---|---|
| Lång et al., Lancet Oncology (2023) | Safety analysis with the first 80,033 women | Similar or higher detection; 44.3% fewer reads | An interim safety analysis, not the final endpoint |
| Hernström et al., Lancet Digital Health (2025) | Secondary outcomes with the full sample | 29% more detection without more false positives | Detection is not the same as patient benefit |
| Gommers et al., The Lancet (2026) | Primary endpoint: interval cancer | Non-inferior, with higher sensitivity and equal specificity | It does not measure mortality; follow-up is two years |
| Eisemann et al., Nature Medicine (2025) | Real-world rollout at 12 German centres | 17.6% more detection without worsening recall | Radiologists voluntarily chose whether to use the tool |
| Jassim et al., BMJ Open (2025) | Review of 31 studies and over 2 million examinations | Reading reduction of 40% to 90% with triage | Interval-cancer follow-up incomplete in several datasets |
2. The missing figure: interval cancers
Identifying a higher volume of cancers doesn’t automatically prove the superiority of a screening initiative. An initiative can boost its detection stats by spotting growths that would have otherwise remained harmless, all while failing to catch the fast-moving ones. The metric designed to capture this flaw is the interval cancer: precisely the one surfacing in the gap between successive screening sessions, meaning the one the process failed to spot.
That constituted the main goal of MASAI, featured in The Lancet in 2026, utilizing a predefined non-inferiority margin of 20%.
| Metric | With AI | Standard double reading |
|---|---|---|
| Interval cancers per 1,000 participants | 1.55 (95% CI: 1.23-1.92) | 1.76 (95% CI: 1.42-2.15) |
| Proportion ratio | 0.88 (95% CI: 0.65-1.18) | p = 0.41: non-inferior |
| Invasive interval cancers | 75 | 89 |
| Interval cancers at stage T2 or above | 38 | 48 |
| Sensitivity | 80.5% (76.4-84.2) | 73.8% (68.9-78.3); p = 0.031 |
| Specificity | 98.5% | 98.5%; p = 0.88 |
The result meets the requirement and adds something more. Not only were there no additional interval cancers, but those that did occur in the AI group tended to be less invasive and at a lower stage, and programme sensitivity rose by nearly seven points without losing a tenth of a point of specificity. It is a clean result, and a rare one in this field.
3. What occurs beyond the trial
A clinical trial is a controlled environment. The next question is whether this holds up in a real programme, and there is a sizeable answer. The PRAIM study, published in Nature Medicine in 2025, followed 463,094 women aged 50 to 69 screened at 12 German centres between July 2021 and February 2023, read by 119 radiologists.
The detection rate in the AI-supported group was 6.7 per 1,000 against 5.7 in the control group: 17.6% more (95% CI: 5.7% to 30.8%), statistically superior. The recall rate was slightly lower and non-inferior, and the positive predictive value rose from 14.9% to 17.9%.
There is one limitation the authors themselves flag and that should not be glossed over: radiologists voluntarily chose whether to use the system, so this is not random assignment and there could be differences between those who used it and those who did not.
4. What the systematic review qualifies
The most extensive synthesis currently accessible was brought to light by Ghufran Jassim and co-authors in BMJ Open in 2025: 31 studies covering more than two million screening examinations across Europe, Asia, North America and Australia.
Their conclusions match the above on the essentials. As a second reader or within double-reading workflows, AI maintains or modestly increases sensitivity — by up to nine percentage points — while preserving or improving specificity; and triage configurations reduce reading volume by between 40% and 90% while maintaining non-inferior detection when thresholds are conservatively calibrated.
But they add two reservations. The first concerns overall certainty: heterogeneity across designs and the use of enriched datasets limit some accuracy estimates, and interval-cancer follow-up is incomplete in several major studies. The second concerns autonomous use: transparent reporting, standardised evaluation and long-term population studies are needed before considering AI as a stand-alone reader.
What to do with this, in practice
Ordered by the strength of the evidence behind it:
• Always ask for the interval-cancer figure. It is the endpoint that separates detecting more from detecting better, and the one MASAI took three years to publish.
• The part illustrated here involves triage and support rather than acting as the sole reader. That approach is what the clinical trial assessed and what the systematic review currently deems safe.
- Examine the supplementary type of tumour identified. Within MASAI, compact invasive malignancies lacking lymph node involvement predominated, perfectly fulfilling the core objective of screening.
- Verify that the recall does not increase. The worth of the outcome stems from spotting more instances without incurring a penalty in false positives.
- Distinguish trial from rollout. The German study featuring 463,094 women boasts a massive scale, yet adoption of the tool remained voluntary, lacking true random assignment.
Frequently asked questions
Does artificial intelligence detect more breast cancers than radiologists?
In supported screening, indeed, this is quantified via a randomised trial. Within MASAI, encompassing 105,934 women derived from Sweden’s national initiative, the detection rate reached 6.4 malignancies per 1,000 evaluations utilising AI, compared to 5.0 through conventional double reading, yielding a ratio of 1.29 (95% CI: 1.09-1.51; p = 0.0021). The artificial intelligence system did not operate autonomously; rather, it triaged examinations and highlighted suspicious areas for the specialist.
Do false positives increase?
Not significantly. In the same trial, the false-positive ratio was 1.01 (95% CI: 0.91-1.11; p = 0.92) and the recall ratio 1.08 (0.99-1.17; p = 0.084), while the positive predictive value of recall improved with a ratio of 1.19 (p = 0.012).
What is an interval cancer and why does it matter so much?
It represents the malignancy developing between consecutive screening intervals, specifically the one missed by the initial examination. Serving as the core objective for MASAI, the findings shared in The Lancet in 2026 indicated 1.55 cases per 1,000 using artificial intelligence compared to 1.76 without it, yielding a proportion of 0.88 (95% CI: 0.65-1.18) that successfully satisfied the non-inferiority benchmark. Absent this metric, merely identifying a higher volume of tumors fails to demonstrate superior screening efficacy.
How many hours of labor does it eliminate?
Around half the reads. MASAI achieved 61,248 reads within the AI cohort compared to 109,692 in the control cohort, representing a 44.2% decrease, whereas the analysis of 31 studies estimates this drop to fall between 40% and 90%, depending on the specific triage approach implemented.
Can AI read mammograms on its own?
Not yet, on the available evidence. The systematic review published in BMJ Open in 2025 concludes that transparent reporting, standardised evaluation and long-term population studies are needed before considering AI as a stand-alone reader, and notes that interval-cancer follow-up is incomplete in several of the available datasets.
What we do not know
• Whether it reduces mortality. No study has measured it: the hardest endpoint available so far is interval cancer at two years.
• What happens across several screening rounds. The published follow-up covers one interval, not a lifetime of successive screens.
- Whether the outcome relies on the specific setup. MASAI utilized a distinct release of a commercial software, and comparative, randomised evaluations between platforms are absent.
• How it behaves in different populations. The large studies are Swedish, Danish and German, with organised screening programmes and relatively homogeneous populations.
References
1. Hernström, V., Josefsson, V. et al. Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI). The Lancet Digital Health, 2025. DOI: 10.1016/s2589-7500(24)00267-x
2. Gommers, J., Hernström, V. et al. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study. The Lancet, 2026. DOI: 10.1016/s0140-6736(25)02464-x
3. Lång, K., Josefsson, V. et al. Artificial intelligence-supported screen reading versus standard double reading in the MASAI trial: a clinical safety analysis. The Lancet Oncology, 2023. DOI: 10.1016/s1470-2045(23)00298-x
4. Eisemann, N., Bunk, S. et al. Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. Nature Medicine, 2025. DOI: 10.1038/s41591-024-03408-6
5. Jassim, G., Otoom, O. et al. Performance of artificial intelligence in breast cancer screening programmes: a systematic review. BMJ Open, 2025. DOI: 10.1136/bmjopen-2025-111360
This material is purely informational and should not be considered medical guidance. The outcomes detailed originate from structured screening initiatives employing dedicated systems and protocols, meaning they cannot be applied directly to alternative clinical environments or personal choices regarding diagnostic procedures.